Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

A common side- or adverse effect from the drug affecting upp to 44% of the patients (PMID 19381453). Typically lymphocyte-rich. Sometimes chylous (PMID�19838099). Management guidelines at PMID�20375898

Publications

Maral S, Bakanay SM, Kucuksahin O, Dilek I

Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020;26(3):738-741

Alter A, Chaisson N, Mukherjee S, Gildea T

A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion.

Chest. 2018;153(2):e33-e36

Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Thorax. 2015;70(7):701-4

Jasielec JK, Larson RA

Dasatinib-Related Pulmonary Toxicity Mimicking an Atypical Infection.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(6):e46-8

Kaiafa G, Kakaletsis N, Savopoulos C, Perifanis V, Giannouli A, Papadopoulos N, Zisekas S, Hatzitolios AI

Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.

Journal of clinical pharmacy and therapeutics. 2014;39(1):102-5

Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013;8(11):1434-7

Breccia M, Alimena G

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.

Leukemia research. 2013;37(6):713-20

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Hematological oncology. 2013;31(2):103-9

Kim D, Goh HG, Kim SH, Cho BS, Kim DW

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

International journal of hematology. 2011;94(4):361-371

Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlögl E, Valent P

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

Haematologica. 2011;96(1):163-6

Breccia M, Alimena G

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Expert opinion on drug safety. 2010;9(5):713-21

Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

The New England journal of medicine. 2010;362(24):2260-70

Masiello D, Gorospe G 3rd, Yang AS

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Journal of hematology & oncology. 2009;2:46

Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA

Dasatinib-induced pleural effusions: a lymphatic network disorder?

The American journal of the medical sciences. 2009;338(5):414-7

Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.

Targeted oncology. 2009;4(2):99-105

de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, Marin D

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.

British journal of haematology. 2008;141(5):745-7

Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J

Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(25):3908-14